Belite Bio (BLTE) Net Equity Issued and Repurchased (2020 - 2025)

Belite Bio (BLTE) posted quarterly Net Equity Issued and Repurchased of $49.3 million for Q4 2025, up 417.13% year-over-year from $9.5 million in Q4 2024, and up 417.13% quarter-over-quarter from $9.5 million in Q4 2024.

Belite Bio (BLTE) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends

Belite Bio's Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $49.3 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Belite Bio 6.40 Bn 6.40 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 49.35 Mn
Dec 31, 2025 49.35 Mn
Dec 31, 2024 9.54 Mn
Dec 31, 2024 9.54 Mn
Dec 31, 2020 23.00 Mn
Dec 31, 2020 23.00 Mn